vs
Side-by-side financial comparison of Genius Sports Ltd (GENI) and Bio-Techne (TECH). Click either name above to swap in a different company.
Genius Sports Ltd is the larger business by last-quarter revenue ($510.9M vs $295.9M, roughly 1.7× Bio-Techne). Bio-Techne runs the higher net margin — 12.8% vs -12.3%, a 25.2% gap on every dollar of revenue. Over the past eight quarters, Genius Sports Ltd's revenue compounded faster (129.2% CAGR vs 4.2%).
Genius Sports is a sports data and technology company that provides data management, video streaming and integrity services to sports leagues, bookmakers and media companies.
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
GENI vs TECH — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $510.9M | $295.9M |
| Net Profit | $-63.0M | $38.0M |
| Gross Margin | 25.2% | 64.6% |
| Operating Margin | -11.5% | 18.4% |
| Net Margin | -12.3% | 12.8% |
| Revenue YoY | — | -6.4% |
| Net Profit YoY | — | 68.3% |
| EPS (diluted) | — | $0.24 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $510.9M | $295.9M | ||
| Q3 25 | $335.4M | — | ||
| Q2 25 | $215.2M | $317.0M | ||
| Q1 25 | $119.7M | $316.2M | ||
| Q4 24 | $413.0M | $297.0M | ||
| Q3 24 | $285.8M | $289.5M | ||
| Q2 24 | $184.1M | $306.1M | ||
| Q1 24 | $97.2M | $303.4M |
| Q4 25 | $-63.0M | $38.0M | ||
| Q3 25 | — | — | ||
| Q2 25 | $-47.3M | $-17.7M | ||
| Q1 25 | $-25.5M | $22.6M | ||
| Q4 24 | $-85.5M | $34.9M | ||
| Q3 24 | $-47.1M | $33.6M | ||
| Q2 24 | $-35.5M | $40.6M | ||
| Q1 24 | $-25.2M | $49.1M |
| Q4 25 | 25.2% | 64.6% | ||
| Q3 25 | 24.2% | — | ||
| Q2 25 | 19.1% | 62.7% | ||
| Q1 25 | 10.7% | 67.9% | ||
| Q4 24 | 16.7% | 65.3% | ||
| Q3 24 | 20.5% | 63.2% | ||
| Q2 24 | 18.6% | 66.4% | ||
| Q1 24 | 9.8% | 67.4% |
| Q4 25 | -11.5% | 18.4% | ||
| Q3 25 | -15.3% | — | ||
| Q2 25 | -21.0% | -7.5% | ||
| Q1 25 | -20.3% | 12.2% | ||
| Q4 24 | -18.0% | 16.0% | ||
| Q3 24 | -13.9% | 13.8% | ||
| Q2 24 | -16.8% | 15.0% | ||
| Q1 24 | -23.7% | 22.1% |
| Q4 25 | -12.3% | 12.8% | ||
| Q3 25 | — | — | ||
| Q2 25 | -22.0% | -5.6% | ||
| Q1 25 | -21.3% | 7.1% | ||
| Q4 24 | -20.7% | 11.7% | ||
| Q3 24 | -16.5% | 11.6% | ||
| Q2 24 | -19.3% | 13.3% | ||
| Q1 24 | -25.9% | 16.2% |
| Q4 25 | — | $0.24 | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $-0.11 | ||
| Q1 25 | — | $0.14 | ||
| Q4 24 | — | $0.22 | ||
| Q3 24 | — | $0.21 | ||
| Q2 24 | — | $0.26 | ||
| Q1 24 | — | $0.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $280.6M | $172.9M |
| Total DebtLower is stronger | — | $260.0M |
| Stockholders' EquityBook value | $724.5M | $2.0B |
| Total Assets | $1.1B | $2.5B |
| Debt / EquityLower = less leverage | — | 0.13× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $280.6M | $172.9M | ||
| Q3 25 | $110.2M | — | ||
| Q2 25 | $110.2M | $162.2M | ||
| Q1 25 | $110.2M | $140.7M | ||
| Q4 24 | $100.3M | $177.5M | ||
| Q3 24 | $100.3M | $187.5M | ||
| Q2 24 | $100.3M | $152.9M | ||
| Q1 24 | $100.3M | $145.3M |
| Q4 25 | — | $260.0M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $346.0M | ||
| Q1 25 | — | $330.0M | ||
| Q4 24 | — | $300.0M | ||
| Q3 24 | — | $300.0M | ||
| Q2 24 | — | $319.0M | ||
| Q1 24 | — | $389.0M |
| Q4 25 | $724.5M | $2.0B | ||
| Q3 25 | $572.4M | — | ||
| Q2 25 | $572.4M | $1.9B | ||
| Q1 25 | $572.4M | $2.0B | ||
| Q4 24 | $573.0M | $2.1B | ||
| Q3 24 | $573.0M | $2.1B | ||
| Q2 24 | $573.0M | $2.1B | ||
| Q1 24 | $573.0M | $2.0B |
| Q4 25 | $1.1B | $2.5B | ||
| Q3 25 | $792.3M | — | ||
| Q2 25 | $792.3M | $2.6B | ||
| Q1 25 | $792.3M | $2.6B | ||
| Q4 24 | $775.7M | $2.7B | ||
| Q3 24 | $775.7M | $2.7B | ||
| Q2 24 | $775.7M | $2.7B | ||
| Q1 24 | $775.7M | $2.7B |
| Q4 25 | — | 0.13× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.18× | ||
| Q1 25 | — | 0.16× | ||
| Q4 24 | — | 0.14× | ||
| Q3 24 | — | 0.14× | ||
| Q2 24 | — | 0.15× | ||
| Q1 24 | — | 0.19× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $81.9M | — |
| Free Cash FlowOCF − Capex | $69.6M | — |
| FCF MarginFCF / Revenue | 13.6% | — |
| Capex IntensityCapex / Revenue | 2.4% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $33.5M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $81.9M | — | ||
| Q3 25 | $-4.8M | — | ||
| Q2 25 | $-1.2M | $98.2M | ||
| Q1 25 | $-14.6M | $41.1M | ||
| Q4 24 | $14.9M | $84.3M | ||
| Q3 24 | $-9.2M | $63.9M | ||
| Q2 24 | — | $75.5M | ||
| Q1 24 | — | $81.0M |
| Q4 25 | $69.6M | — | ||
| Q3 25 | $-14.2M | — | ||
| Q2 25 | $-5.8M | $93.3M | ||
| Q1 25 | $-16.0M | $31.0M | ||
| Q4 24 | $11.3M | $77.5M | ||
| Q3 24 | $-11.6M | $54.7M | ||
| Q2 24 | — | $57.5M | ||
| Q1 24 | — | $64.5M |
| Q4 25 | 13.6% | — | ||
| Q3 25 | -4.2% | — | ||
| Q2 25 | -2.7% | 29.4% | ||
| Q1 25 | -13.4% | 9.8% | ||
| Q4 24 | 2.7% | 26.1% | ||
| Q3 24 | -4.1% | 18.9% | ||
| Q2 24 | — | 18.8% | ||
| Q1 24 | — | 21.3% |
| Q4 25 | 2.4% | — | ||
| Q3 25 | 2.8% | — | ||
| Q2 25 | 2.1% | 1.5% | ||
| Q1 25 | 1.2% | 3.2% | ||
| Q4 24 | 0.9% | 2.3% | ||
| Q3 24 | 0.9% | 3.2% | ||
| Q2 24 | — | 5.9% | ||
| Q1 24 | — | 5.4% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 1.82× | ||
| Q4 24 | — | 2.42× | ||
| Q3 24 | — | 1.90× | ||
| Q2 24 | — | 1.86× | ||
| Q1 24 | — | 1.65× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GENI
Segment breakdown not available.
TECH
| Diagnostics And Spatial Biology | $81.2M | 27% |
| EMEA Excluding UK | $75.4M | 25% |
| Other | $42.4M | 14% |
| Instruments | $29.6M | 10% |
| APAC Excluding Greater China | $22.7M | 8% |
| Services | $22.3M | 8% |
| GB | $13.7M | 5% |
| Royalty | $8.5M | 3% |
